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Abstract
The mediators of the DNA damage response (DDR) are highly phosphorylated by kinases that control cell proliferation, but
little is known about the role of this regulation. Here we show that cell cycle phosphorylation of the prototypical DDR
mediator Saccharomyces cerevisiae Rad9 depends on cyclin-dependent kinase (CDK) complexes. We find that a specific G2/
M form of Cdc28 can phosphorylate in vitro the N-terminal region of Rad9 on nine consensus CDK phosphorylation sites. We
show that the integrity of CDK consensus sites and the activity of Cdc28 are required for both the activation of the Chk1
checkpoint kinase and its interaction with Rad9. We have identified T125 and T143 as important residues in Rad9 for this
Rad9/Chk1 interaction. Phosphorylation of T143 is the most important feature promoting Rad9/Chk1 interaction, while the
much more abundant phosphorylation of the neighbouring T125 residue impedes the Rad9/Chk1 interaction. We suggest a
novel model for Chk1 activation where Cdc28 regulates the constitutive interaction of Rad9 and Chk1. The Rad9/Chk1
complex is then recruited at sites of DNA damage where activation of Chk1 requires additional DDR–specific protein kinases.
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Introduction
Eukaryotic cells have developed highly conserved surveillance
pathways known as the DNA damage response (DDR) to preserve
genome integrity after genotoxic insult. These pathways inhibit
replication and segregation of damaged DNA by activating
checkpoints and regulating transcription, replication and repair
[1].Defects in theDDRcontribute to human cancer primarily due to
defective induction of apoptosis and senescence [2].
Central to theDDRare protein kinases that are activated byDNA
lesions. The human phosphatidylinositol 3-kinase-like kinases
(PIKKs), ATM, ATR and DNA-PK occupy central points in the
DNA damage-induced signalling pathways [1,3]. ATM corresponds
to Tel1, and ATR corresponds to Mec1 in Saccharomyces cerevisiae and
Rad3 in Schizosaccharomyces pombe [3] ; DNA-PK does not exist in the
budding and fission yeast model systems. Once activated by DNA-
protein structures generated in response to lesions, PIKKs regulate
numerous DDR proteins including the downstream ‘checkpoint’
kinases Chk1 (in all three species) and Chk2 (Rad53 or Cds1 in
budding and fission yeast respectively). These two ‘effector’ kinases in
turn phosphorylate target proteins leading to the downstream
biological consequences of DDR activation [4].
DNA damage response mediators contribute to the PIKK-
dependent activation of checkpoint kinases by acting as molecular
adaptors that facilitate protein-protein interactions at sites of DNA
damage [5–7]. The first checkpoint protein identified was S.
cerevisiae Rad9 [8] and this is the prototypical DDR mediator.
Rad9 is a 148 kDa protein required for cell survival in response to
DNA damage. It is homologous to S. pombe Crb2 [9,10] and shares
functional and structural similarities with three human mediators
53BP1, MDC1 and BRCA1 [5–7]. Rad9 is required throughout
the cell cycle for checkpoint delays [11], but also has other
functions in the DDR including roles in DNA repair [12–15].
Mediators are typically phosphoproteins that are modified
by multiple kinases including the PIKKs as a result of DNA
damage [9,16–22]. DNA damage-induced and PIKK-dependent
PLOS Genetics | www.plosgenetics.org 1 April 2013 | Volume 9 | Issue 4 | e1003310
phosphorylation of budding yeast Rad9 is required for its
oligomerisation [23] and activation. PIKK-dependent Rad9
phosphorylation occurs once the mediator is recruited to the
damaged chromatin by either of two redundant recruitment
pathways [24]. One is dependent on the interaction of Rad9 with
two histone modifications and the other is independent of these
modifications but involves Rad9 interaction with the Dpb11
mediator. DNA damage-induced Rad9 phosphorylation correlates
with the remodeling of a $850 kDa Rad9 complex into a smaller
560 kDa complex containing the DNA damage-induced hyper-
phosphorylated form of Rad9 [25,26]. This mediates Rad9
function as an adaptor-catalyst for activation of the Rad53 kinase
[25–27]: Rad9 is hyperphosphorylated by PIKKs once recruited
to sites of DNA damage and this generates a recruitment surface
for Rad53, which in turn is also phosphorylated by PIKKs to
become pre-activated. Full activation of Rad53 requires its in trans
autophosphorylation, catalyzed by the increased local concentra-
tion of Rad53 at the Rad9 scaffold [27].
Chk1 activation is well conserved from yeast to human. PIKK-
dependent phosphorylation of its C-terminal region allows Chk1
to switch from an inactive to an active state in response to DNA
damage [28,29]. This is followed by in cis autophosphorylation on
the same C-terminal region [30], which is presumed to be
important for the propagation of the human CHK1 signal in the
nucleus [30]. Chk1 in cis autophosphorylation upon DNA damage
is also conserved in budding yeast [31] suggesting that it could
have the same function as its human counterpart.
ATR phosphorylation of human CHK1 depends on a variety of
DNA damage mediators [4]. Of these, claspin-dependent activa-
tion of CHK1 is the best characterised and involves PIKK-
dependent phosphorylation of claspin itself [32,33]. The ortholo-
gue of claspin in both budding and fission yeast is Mrc1 although
in the DNA replication checkpoint budding yeast Mrc1 primarily
regulates Rad53, rather than Chk1 [34]. In both yeast models the
Rad9/Crb2 mediator proteins have been mostly implicated in
Chk1 activation after DNA damage through their scaffolding
role. Their N-terminal region is also known to be important for
Chk1 activation although the specific mechanism is not well
characterised [35,36]. Rad9-like mediator proteins in higher cells,
including BRCA1 and MDC1, play complex roles in CHK1
activation that are not entirely understood [4,32].
DDR induction after DNA double-strand breaks (DSBs)
involves cyclin-dependent kinases (CDKs) in addition to the
recognition and processing of the breaks [37]. CDK activity
controls the generation of single-strand DNA, leading to the
amplification of the checkpoint signal by stimulating the switch
from ATM to ATR activity, as well as impacting upon the choice
of DSB repair mechanisms [4,37]. CDK activity might also
regulate other DDR proteins not necessarily involved at the DSB
processing step [4,37]. For example, CDK activity regulates
multiple steps of the homologous recombination process [37].
DNA damage mediators are frequently phosphorylated during
cell cycle progression in the absence of exogenous DNA damage
[19,20,38–41]. The ‘Rad9-like’ mediators share a large number of
consensus motifs for phosphorylation by CDKs (S/T-P-x-K/R or
minimal S/T-P sites) but their functions remain unknown. Rad9
contains an exceptionally high density of CDK motifs with twenty
S/T-P sites of which nine conform to the full consensus [42,43]. In
undamaged cells the mobility of Rad9 during electrophoresis
suggests that it is heavily modified. Phosphatase-sensitive modified
forms with slow mobility in SDS PAGE have been observed in S
and M phase-arrested cells [20]. Not surprisingly, Rad9 has been
identified as a CDK substrate in vitro [43,44]. To date mass
spectrometric studies support the in vivo phosphorylation of 15 of
these CDK consensus sites [45–47], although the biological role of
CDK-dependent phosphorylation of Rad9 is not well charac-
terised.
Here we have investigated the phosphorylation of Rad9 during
the S, G2 and M phases of the cell cycle and found that it is
mediated by the Cdc28/Clb complexes. Cdc28 is the S. cerevisiae
counterpart of human CDK1, and can bind six different cyclin B
equivalents, Clb1-6. We show that the N-terminal region of Rad9
containing 9 consensus CDK phosphorylation sites is specifically
phosphorylated in vitro by Cdc28/Clb2. Mutational analyses
indicate that the N-terminal consensus CDK sites in Rad9
regulate a DNA damage-independent interaction between Chk1
and Rad9, as well as the activation of Chk1-dependent but Rad53-
independent, signalling after DNA damage. We show that two
CDK sites T125 and T143 are of particular importance for Rad9-
dependent Chk1 activation. Our results suggest that phosphory-
lation of T143 stimulates Rad9 interaction with Chk1, whereas
phosphorylation of T125 is inhibitory. We present a model in
which prior CDK-dependent phosphorylation of the Rad9 N-
terminus during S, G2 and M phases is required for the interaction
between Chk1 and Rad9. PIK kinase-dependent phosphorylation
of both Chk1 and Rad9 at sites of DNA damage is then followed
by Chk1 activation and its release from site of DNA damage
simultaneously with Rad9.
Results
DNA damage-independent phosphorylation of Rad9
during S, G2, and M requires Cdc28/Clb activity
Rad9 is phosphorylated in the absence of DNA damage
([11,17,20] and Figure S1), and as a result it migrates in SDS-
PAGE with an apparent mobility ranging from 180 to 220 kDa
[20]. These Rad9 phospho-forms found in normally cycling cells
have faster mobility [48] than the slowest Mec1/Tel1-dependent
migrating forms of Rad9 observed in response to DNA damage
[11,17,20,48]. To more clearly distinguish between the DNA
damage and cell cycle regulated forms of Rad9, here we term the
former as D-Rad9 and the latter as C-Rad9. C-Rad9, previously
Author Summary
Human cells activate the DNA damage response (DDR) to
repair DNA damage and to prevent cells with DNA damage
from proliferating. Alterations to the DDR are strongly
implicated in the development of cancer. Using the
budding yeast model system, we have studied how the
regulation of the key DDR component Rad9 is integrated
into cell cycle control. The cyclin-dependent kinase Cdc28
that regulates the yeast cell cycle also extensively
phosphorylates Rad9 during cell cycle progression. We
show here that Cdc28 controls Rad9 function in the
activation of the important downstream DNA damage
effector kinase Chk1. Two sites of phosphorylation in the
N-terminus of Rad9 are crucial for the physical interaction
between Rad9 and Chk1 regulated by Cdc28. We propose
a novel model for Chk1 activation whereby a subset of
Rad9 and Chk1 interacts constitutively in the absence of
DNA damage. The Rad9/Chk1 complex is recruited to sites
of DNA damage where activation of Chk1 involves
additional DDR–specific protein kinases. Human cells
contain multiple Rad9-like proteins that are also known
to be cell cycle phosphorylated in the absence of
exogenous DNA damage, suggesting that our observa-
tions may have important implications for DDR regulation
in human cells.
CDK Regulates Rad9/Chk1 Interaction
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termed hypo-phosphorylated Rad9, was originally detected in S or
M, but not G1, arrested cells [20].
To exclude the possibility that C-Rad9 phosphorylation forms
were mainly induced in response to cell cycle arrest treatment, we
determined the phosphorylation profile of Rad9 during normal
cell cycle progression in an arrest and release experiment
(Figure 1A). The fastest migrating C-Rad9 forms were detected
in cells progressing through G1 phase, with slower migrating C-
Rad9 forms appearing as cells entered S phase and persisting with
ever decreasing mobility as cells moved through S, G2 and into
mitosis (Figure 1A). These slower forms disappeared towards the
end of mitosis, with the fastest migrating form of C-Rad9
reappearing in G1 cells in a pattern that can be observed over
at least 2.5 cell cycles. This indicates that C-Rad9 phosphorylation
occurs during normal cell proliferation from S to M phases in the
absence of DNA damage and not only in S or M phase-induced
cell cycle arrests. Interestingly, the cyclic pattern of Rad9
phosphorylation directly mirrors the cell cycle activity of budding
yeast Cdc28, which regulates cell cycle progression by association
with 9 different cyclins [49]. The Cdc28/Cln1-3 complexes are
active in G1 phase and have lower kinase activity than the Cdc28/
Clb1-6 complexes that function specifically in S, G2 and mitosis
[49]. Interestingly, Rad9 was identified as one of 360 proteins to
be phosphorylated in vitro by Cdc28/Clb2 and Cdc28/Clb5
complexes [43,44]. We hypothesised that Rad9 is increasingly
phosphorylated during passage through S, G2 and M phases of the
cell cycle, and that the Cdc28/Clbs complexes are responsible for
Rad9 cell cycle phosphorylation profile in vivo.
We first tested the hypothesis that the in vivo phosphorylated
forms of Rad9 observed during cell cycle progression require
Cdc28 activity. We used cells expressing Cdc28-as1, an analogue-
sensitive mutant of Cdc28 [50] in which Cdc28-as1 is inactivated
within 5–15 minutes in the presence of the bulky non-hydrolysable
ATP analogue 1-NMPP1. Dephosphorylation of Cdc28 substrates
under these conditions is then dependent upon counteracting
phosphatases [43]. We followed inactivation of Cdc28-as1 [43] by
monitoring dephosphorylation of Orc6, a known Cdc28 target
[51]. The slower migrating forms of C-Rad9 detected in
asynchronous and nocodazole-arrested G2/M cells were com-
pletely abolished as a consequence of this Cdc28 inactivation
(Figure 1B). The migration of Rad9 in G1 arrested cells was not
affected by the inactivation of Cdc28. Thus, the increasing
phosphorylation of Rad9 detectable as decreased electrophoretic
mobility of Rad9 when cells progress through S, G2 and M phase
is dependent upon Cdc28.
The B type cyclins Clb1-6 are candidate cyclin partners of
Cdc28 required for Rad9 cell cycle phosphorylation. We therefore
examined C-Rad9 gel mobility in temperature sensitive mutants
with different levels of Cdc28/Clb activity at the non-permissive
temperature (Figure 1C). Cdc4 is an F-box protein of the SCF E3
ubiquitin ligase complex that determines substrate specificity and
is required for destruction of Sic1, a potent inhibitor of CDK
complexes containing B-type cyclins [49]. We generated G1 cells
with high levels of Sic1 by arresting cdc4-1 cells with a-factor and
shifting to the restrictive temperature [52–54] (Figure 1C left
panels). Upon release from the a-factor block, cell cycle
progression was inhibited and cell cycle-dependent phosphoryla-
tion of Rad9 remained severely abrogated in cdc4-1 cells
containing low CDK activity. The abrogation of Rad9 cell cycle
phosphorylation is dependent upon Sic1 because cell cycle
phosphorylation of Rad9 is restored in similarly treated cdc4-1
sic1D cells (indicated by retarded mobility in Figure 1C middle
panels). Rad9 is phosphorylated even during a-factor arrest as a
consequence of increased Cdc28/Clb activity due to the absence
of Sic1 in these conditions. Rad9 phosphorylation was observed in
similarly treated cdc7-1 cells, which also block cell cycle
progression and DNA replication prior to S phase but unlike
cdc4-1 cells have a low level of Sic1 and correspondingly high
CDK activity (Figure 1C right panels). This confirms that Cdc28/
Clb complexes are needed for Rad9 cell cycle phosphorylation.
We also established that Rad9 can be phosphorylated irrespective
of whether DNA synthesis takes place or not by manipulating the
levels of the Cdc6 protein required for the initiation of DNA
synthesis (Figure S1B). Together, our data indicate that Rad9 cell
cycle phosphorylation is dependent upon B-type cyclin forms of
the major CDK of budding yeast and is independent on the
generation of S phase structures.
CDK sites 1–9 in the CAD region of Rad9 are
phosphorylated by Cdc28/Clb2
Nine of the 20 consensus CDK phosphorylation sites of Rad9
are located in the N-terminal 231 residues (Figure 2A) referred to
as the Chk1 Activating Domain (CAD) [35] and are likely targets
for Cdc28/Clb complexes. First, we established that Cdc28/Clb
complexes are capable of phosphorylating the CAD region in vitro
using the four major classes of cyclin-Cdc28 complexes as
described by Ko˜ivoma¨gi and collaborators [55]. Essentially, the
Cln2 form is G1-specific, the Clb5 form is S-specific, the Clb3
form is G2-specific and the Clb2 form is mitosis-specific. We
purified these four complexes (Figure S2A) and tested their ability
to phosphorylate a recombinant Rad9 CAD region relative to the
standard histone H1 substrate used in Cdc28 kinase assays
(Figure 2B). We observed that the Rad9 CAD region was
preferentially phosphorylated by the Cdc28/Clb2 kinase with a
profile similar to histone H1, although H1 was phosphorylated to
higher levels (Figure 2B). Strikingly, no phosphorylation was
observed when the recombinant CADCDK1-9A lacking all 9 CDK
sites due to alanine substitution of the serine and threonine
residues was used as a substrate (Figure 2B) even in the presence of
increased amounts of kinase (Figure S2B). These results indicate
that the sites targeted by the Cdc28/Clb2 complex in vitro are
among the 9 CDK consensus sites in the CAD region.
To determine whether the 9 CDK consensus sites in Rad9 are
phosphorylated in vivo, we then compared a mutant strain
rad9CDK1-9A expressing a Rad9 protein, in which the four serines
and the five threonines corresponding to CDK sites 1–9 were
mutated to alanines (Figure 2A and Figure S2C), with rad9CADD
cells, which express a truncated Rad9 protein lacking the CAD
region and are defective for Chk1 activation [35,56]. We used
Western analysis to determine the extent of Rad9 cell cycle
phosphorylation in rad9CDK1-9A cells (Figure S2D). The detection of
slower migrating forms of Rad9CDK1-9A is in agreement with our in
vitro phosphorylation assay (see Figure 2B) and consistent with at
least some of the CDK sites mutated in Rad9CDK1-9A being
phosphorylated in vivo (Figure S2D).
CDK sites in the Rad9 CAD are specifically required for
Chk1 activation in G2/M phase
The CAD region has been identified as necessary for Chk1
activation by damage-dependent phosphorylation through an
unknown mechanism [35]. We hypothesized that Cdc28-depen-
dent phosphorylation of some or all of the 9 CDK consensus sites
in the CAD region (here termed CDK1-9) is important for Chk1
activation. The ability of the CDK1-9 sites to mediate Chk1
activation was assessed by analysing the DNA damage-induced
phospho-shift of tagged Chk1-3HA by immunoblotting as
previously described [57]. A lower mobility Chk1 phospho-form
CDK Regulates Rad9/Chk1 Interaction
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rapidly appears in response to bleocin treatment of asynchronously
growing wild type cells (Figure 2C). As reported earlier, Chk1
activation in this assay was defective in rad9D and rad9CADD cells
[35,57]. The damage-induced Chk1 phospho-shift was also
abrogated in rad9CDK1-9A cells. Similar results were obtained in
response to 4-NQO (Figure S2E).
A comparison of G1 and G2/M arrested cells revealed that
mutation of CDK 1–9 sites to alanine caused severe defects in
Chk1 activation after bleocin treatment in G2/M cells, although
there was some residual activation in G1 arrested cells (Figure 2D
and 2E). Similar results were obtained with IR, 4-NQO and UV
(Figure S2F). Thus, the dependence of Chk1 activation on CDK
sites 1–9 correlates well with elevated CDK activity and Rad9 cell
cycle phosphorylation in G2/M. Our results are consistent with a
role for the CDK sites of the Rad9 CAD region in the regulation
of DNA damage-induced Chk1 kinase activity.
An important aspect of the role of the Rad9 CAD region is its
specificity in Chk1 regulation [35]. We observed that the
formation of D-Rad9 is largely unaffected in Rad9CDK1-9A cells
(Figure 3A and Figure S3A) similar to rad9CADD cells. We also
found that activation of Rad53 in G2/M arrested rad9CDK1-9A cells
after DNA damage is mostly normal (Figure 3B and Figure S3B).
The minor defect in Rad53 activation we observed in both
rad9CDK1-9A and rad9CADD cells can be explained by loss of CDK
site 1 (Serine 11), known to be involved in the recruitment of
Dpb11 [58], which in turn is required for efficient Rad53
Figure 1. Rad9 is phosphorylated by Cdc28 in the absence of DNA damage. (A) Cell cycle regulation of phosphorylated forms of Rad9. An a-
factor block and release experiment using yeast strain CG378. Rad9 phospho-forms were identified in protein extracts by western blotting. The
phospho-protein Swi6 serves as a loading control. The cell cycle phases of synchronously cycling cells determined by budding analysis are indicated
above the blots. The insert in the graph shows Rad9 from asynchronously growing cells or cells arrested with a-factor, HU or nocodazole. (B) Rad9
phosphorylation is dependent on Cdc28 activity. Rad9 and Orc6 western blots performed with extracts prepared from asynchronously growing, a-
factor (G1) or nocodazole (G2/M) arrested cdc28-as1 cells either mock or 1-NMPP1 treated. (C) Rad9 phosphorylation is dependent on Cdc28/Clb
activity. The indicated cells were arrested with a-factor, shifted to 30uC and samples were taken at the indicated times for Rad9 western and FACS
analysis. See also Figure S1 for related experiments.
doi:10.1371/journal.pgen.1003310.g001
CDK Regulates Rad9/Chk1 Interaction
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activation [59,60]. However, mutation of CDK site 1 alone does
not abolish DNA damage phosphorylation of Chk1 (see below and
Figure S6B) suggesting that one or more of the CDK1-9 sites are
required for Chk1 activation.
To confirm that the CDK1-9 sites function principally in the
Chk1 activation pathway we performed an epistasis analysis using
a standard G2/M cell cycle checkpoint assay ([11] and Text S1).
Cells were synchronized in G2/M using nocodazole and released
Figure 2. N-terminal CDK consensus sites are phosphorylated by Cdc28/Clb2 and are required for activation of Chk1 in vivo. (A)
Schematic representation of the Rad9 N-terminus showing the 9 consensus sites for phosphorylation by Cdc28 and those mutated to alanine in
Rad9CDK1-9A mutant protein. (B) In vitro phosphorylation of Rad9 CADWT, but not CADCDK1-9A, requires Cdc28/Clb2. In vitro kinase assays were
performed on the indicated substrates with four specific purified Cdc28 complexes. (C) DNA damage-dependent Chk1 phosphorylation is defective in
rad9CDK1-9A, rad9CADD and rad9 D cells. Asynchronously growing cells were treated with bleocin for the indicated times and Chk1 phosphorylation
analysed by western blotting. (D&E) Chk1 activation is mostly dependent on the 9 CAD CDK consensus sites in G2/M cells. Cells were grown and
arrested in the cell cycle as indicated with either a-factor (G1 cells in D) or nocodazole (G2/M cells in E), treated with bleocin for the indicated times
and analysed by western blotting of Chk1-3HA (D & E). See also Figure S2 for related experiments.
doi:10.1371/journal.pgen.1003310.g002
CDK Regulates Rad9/Chk1 Interaction
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through mitosis using medium without nocodazole but containing
a-factor to prevent these cells from cycling further by arresting
them in G1 phase. The G2/M delay measured in this assay is the
DNA damage-induced delay in completing mitosis observed in
treated cells compared to untreated cells. This delay requires
Rad9-dependent regulation of two additive pathways involving
both the Chk1 and Rad53/Chk2 checkpoint kinases [57,61].
rad9CDK1-9A cells displayed a partially defective G2/M checkpoint
similar to single deletion of chk1D or rad53D (Figure 3C). A similar
partial defect was also observed in rad9CDK1-9A chk1D cells, whereas
rad9CDK1-9A rad53D cells were completely defective in this G2/M
checkpoint assay. The epistatic relationship between rad9CDK1-9A
and chk1D and the additive relationship between rad9CDK1-9A and
rad53D together strongly indicate that the CDK1-9 sites of Rad9
function specifically to regulate Chk1 activation in response to
DNA damage.
Figure 3. The CDK1-9 sites of Rad9 specifically function in the Chk1 branch of the G2/M checkpoint. rad9CDK1-9A mutant cells arrested in
G2/M by nocodazole treatment are neither defective for Rad9 (A) nor for Rad53 (B) phosphorylations induced by bleocin treatment started at time 0.
(C) The CDK1-9 sites of Rad9 function specifically in the Chk1 branch and not the Rad53 branch of the G2/M checkpoint. The indicated strains were
examined for epistatic relationships using the G2/M checkpoint assay, in which cells synchronized in G2/M using nocodazole are released after
irradiation into medium without nocodazole, but containing a-factor, preventing cells that have successfully completed mitosis from cycling
further by arresting them in G1. This assay measures the delay in completing mitosis under DNA damaging conditions by comparing the behavior
of cells that have been irradiated with IR (+IR) or not (2IR). All strains contained the sml1D mutation necessary for the viability of rad53D cells. See
also Figure S3.
doi:10.1371/journal.pgen.1003310.g003
CDK Regulates Rad9/Chk1 Interaction
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CDK-dependent activation of Chk1 controls Rad9/Chk1
interaction
Chk1 activation in response to DSBs requires the activity of
Cdc28 and this has been attributed to a key role for Cdc28 in
controlling DSB resection [49,62]. To obtain evidence for a role of
Cdc28 in Chk1 control independently of Cdc28-dependent
regulation of DSB resection, we used cdc28-as1 cells, in which
Cdc28 can be rapidly inhibited, arrested in G2/M and exposed to
4-NQO. These conditions do not result in DSBs as 4-NQO lesions
(single strand breaks and DNA adducts repaired by NER) cannot
be processed or converted in DSBs by replication forks in G2/M
arrested cells. As a control we used bleocin treatment, which
directly induces DSBs. Cdc28 activity was essential for Chk1
activation in response to either 4-NQO or bleocin (Figure 4 and
Figure S4A). Furthermore, both Rad53 and Rad9 activation after
4-NQO treatment was independent of Cdc28 activity, unlike
activation of Rad53 in response to bleocin. This is in agreement
with the reported role of Cdc28 in DSB processing [62]. These
results suggest that Chk1 activation upon DNA damage is
absolutely dependent upon Cdc28 activity, rather than a
downstream consequence of Cdc28-dependent resection that
occurs at DSBs. We also observed that maintenance of Chk1
signaling requires continuous Cdc28 activity [62] (Figure S4B and
S4C). Our results indicate that Cdc28 activity is essential for
initiation and maintenance of Chk1 activation with all DNA
damaging agents tested. They are also consistent with control of
Chk1 activation by Cdc28-dependent phosphorylation of CDK
sites in the N-terminus of Rad9.
A mechanistic clue as to how Chk1 could be activated by Rad9
comes from the reported interaction between these proteins in
yeast two-hybrid (Y2H) assays [57]. Therefore, we tested whether
this interaction depends on the 9 CDK sites in the Rad9 N-
terminal region. Both full length Rad9 and the N-terminal Rad9
CAD region interact with Chk1 (Figure 5A). Importantly, the
interaction between full length Rad9 and Chk1 absolutely
required intact CDK1-9 sites, consistent with CDK-dependent
phosphorylation of these sites regulating the interaction between
Rad9 and Chk1. Using a triple-plasmid based Y2H assay (see Text
S1 and [58]) we could monitor both the cell cycle and the Cdc28
dependency of the interaction by synchronising cdc28-as1 cells in
G1 and G2/M phases. In support of our hypothesis, we observed
that inhibition of Cdc28-as1 activity in G2/M arrested cells
resulted in loss of this interaction (Figure 5B). Consistent with the
Rad9-dependent Chk1 activation observed after DNA damage
observed in G1 cells (Figure 2D), the Y2H interaction between
Rad9 and Chk1 was also detected in G1 arrested cells although it
was clearly Cdc28-independent (Figure 5B). Therefore, a Cdc28-
independent mechanism must exist that regulates the Rad9/Chk1
interaction in G1 phase. This interaction still requires the integrity
of the CDK1-9 sites in G1 phase (Figure S5A) and is consistent
Figure 4. CDK is required for the activation of Chk1-dependent signaling. Cdc28 activity was regulated using the 1-NMPP1 inhibitor in G2/
M arrested cdc28-as1 cells treated with bleocin or 4-NQO to examine the activation of Chk1 signaling. Rad9 and Rad53 were followed as markers of
checkpoint activation, while Orc6 phosphorylation serves as a marker for Cdc28 inactivation. See also Figure S4.
doi:10.1371/journal.pgen.1003310.g004
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with the decreased Chk1 activation observed in G1 arrested
rad9CDK1-9A cells (Figure 2D). Importantly, our yeast two-hybrid
analyses demonstrate that in the G2/M phase of the cell cycle the
interaction between Rad9 and Chk1 is fully dependent on the
Rad9 CAD, on the nine CDK sites located in this region, and on
the activity of Cdc28 during the G2/M phase of the cell cycle.
Next, we used co-immunoprecipitation in cell extracts to study
the interaction between Rad9 and Chk1 expressed at endogenous
levels to confirm our Y2H Rad9/Chk1 interaction results
(Figure 5C and 5D). We observed a Rad9/Chk1 interaction in
immunoprecipitation experiments performed with extracts pre-
pared from G2/M arrested wild type cells that had been either
Figure 5. CDK-dependent phosphorylation of the nine N-terminal CDK sites in Rad9 regulates a physical interaction between Rad9
and Chk1. (A) Rad9/Chk1 interaction measured in vivo using a yeast two-hybrid (Y2H) assay is dependent on the CDK1-9 sites. Y2H interaction of
specific bait and prey plasmids shown on the left is indicated by the white colour of the otherwise red cells, their resistance to Aureobasidin A and
their blue colour on media containing the X-a-gal substrate, as for the p53/T antigen interaction control. Six independent clones are presented for
each vector combination. (B) The Y2H interaction between Rad9 and Chk1 is dependent on CDK activity in G2/M cells. The indicated bait and prey
plasmids were introduced into cdc28-as1 cells mock treated or treated with 1-NMPP1 1 h after synchronization of cells with either nocodazole or
alpha factor and prior to induction of expression of each bait protein. The recently reported CDK-dependent Rad9/Dpb11 interaction was used as a
positive control. (C) The Rad9/Chk1 interaction measured using co-immunoprecipitation (co-IP) occurs both in the absence and presence of DNA
damage. Chk1 (anti-FLAG) and Dpb11 (anti-MYC) immunoprecipitations (IPs) were performed as indicated on extracts prepared from nocodazole-
arrested cells, expressing both Chk1-3FLAG and Dpb11-13MYC, and either mock treated or treated with 20 mg/ml of bleocin for 45 min. Mock (IgG) or
Dpb11 (MYC) IPs were performed as controls. Rad9, Chk1-3FLAG and Dpb11-13MYC specific bands were detected in western blots. Lower exposures,
to facilitate their visualisation, of the western blots of the starting extracts are shown to the left. (D) Chk1 interaction with Rad9 is dependent on the
CDK1-9 sites. As in panel C, except rad9CDK1-9A cells were used. See also Figure S5 for related experiments.
doi:10.1371/journal.pgen.1003310.g005
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mock or bleocin-treated (Figure 5C). Rad9 can be detected in
Chk1-3FLAG immunoprecipitates independently of DNA damage
(Figure 5C). Notably, after DNA damage Chk1 preferentially
associated with Mec1/Tel1-phosphorylated D-Rad9 even though
the Cdc28-dependent C-Rad9 phospho-forms were the major
forms detected in the whole cell extracts. The Rad9/Chk1
interaction was also observed in reciprocal co-immunoprecipita-
tion experiments in which Rad9-9MYC was immunoprecipitated
from G2/M arrested cells treated with bleocin (Figure S5B).
Although both immunoprecipitations are efficient they do not
result in significant depletion of the co-immunoprecipitated
protein indicating that only a small fraction of the total pool of
Rad9 and Chk1 are bound to each other in our extracts (Figure
S5C and S5D). In parallel experiments we observed that the
Chk1/Rad9 interaction is abolished when the CDK1-9 sites are
mutated since Rad9CDK1-9A is not detected in Chk1 immunopre-
cipitates from extracts prepared from either mock or bleocin
treated rad9CDK1-9A cells (Figure 5D). Thus, co-immunoprecipita-
tion experiments agree with our Y2H analyses and demonstrate
that Rad9/Chk1 complex formation is fully dependent on the nine
CDK sites located in the Rad9 CAD region. In addition, the co-
immunoprecipitation experiments reveal that the Rad9/Chk1
interaction occurs independently of DNA damage.
To understand better the regulation of Chk1 activation, we
compared the Rad9/Dpb11 interaction reported earlier [58] to the
Rad9/Chk1 interaction reported here. After DNA damage Chk1
only interacts with D-Rad9 whereas Dpb11 can still interact with C-
Rad9 as well as D-Rad9 (Figure 5C). The DNA damage interaction
between Rad9 and Dpb11 was lost in bleocin treated rad9CDK1-9A
cells, which is in agreement with our previous finding that Ser11
(CDK site 1) is necessary for Rad9 interaction with Dpb11 [58].
Thus, the Ser11-dependent Rad9/Dpb11 interaction is only
detected after DNA damage in contrast to the constitutive CDK
site-dependent Rad9/Chk1 interaction. Perhaps reflecting different
abundances of Dpb11 and Chk1 in cells, the extent of Dpb11
interaction with Rad9 in the presence or in absence of DNA
damage appeared much less than we observed for the Chk1/Rad9
interaction under similar conditions. Importantly, Dpb11 was never
observed in the Chk1 immunoprecipitates and Chk1 was absent
from Dpb11 immunoprecipitates, indicating the presence of two
mutually exclusive Rad9 sub-complexes. Taken together, our results
indicate that CDK-dependent phosphorylation of consensus CDK
sites in the N-terminal region of Rad9 is required for an interaction
between Chk1 and Rad9 that occurs both in the presence and in the
absence of DNA damage treatments.
To understand how Chk1 can be released from the Rad9/Chk1
complex in response to DNA damage, we used the in vitro assay
previously reported that demonstrated that Rad53 could be
released from the Rad9/Rad53 complex in vitro by addition of
ATP [11,25,26]. Rad9 complexes were washed and incubated
with either ATP, its non-hydrolysable analogue ATP-cS, or mock
treated. As previously reported, Rad53 became further auto-
phosphorylated and was released into the supernatant in a manner
dependent upon ATP hydrolysis (Figure S5E) [26]. In contrast,
Chk1 phosphorylation was not further modified by ATP addition
and it was not released from the Rad9 beads. These in vitro
observations are consistent with a distinct molecular mechanism
involving an ATP-dependent release from the Rad9 complex for
the regulation of Rad53, but not for Chk1.
Differential regulation of Rad9/Chk1 interaction by T125
and T143 phosphorylation
The next step to understanding the regulation of the Rad9/
Chk1 interaction was to identify the specific sites in the CAD
region involved. Our initial attempt to address this question using
Rad9CDK mutants containing different combinations of mutant
sites was inconclusive (Figure S6). We therefore generated Y2H
CAD mutant constructs in which each of the individual nine sites
in the CADCDK1-9A mutant was mutated back to the wild type
residue. The ability of these nine ‘reversion’ mutants to interact
with Chk1 was assessed by the Y2H assay (Figure 6A). When
alanine residues at CDK sites 6 and 7 at position 125 and 143
were individually restored to threonines, each reversion sustained
significant Rad9/Chk1 interaction. The combined reversion of
T125 with T143 did not further increase the Rad9 CAD/Chk1
interaction (Figure S6C). We further assessed the contribution of
both positions by mutating T125 and T143 simultaneously to
alanine (CAD6A7A) in an otherwise wild type Rad9 CAD. The
Y2H interaction with Chk1 was strongly reduced, although
residual interaction relative to mutation of all 9 CDK sites was
detected (Figure S6D), suggesting that other sites within the Rad9
CAD might also contribute to the Rad9/Chk1 interaction. Taken
together, the Y2H results reveal that the integrity of residues T125
and T143 is particularly important for the interaction between the
Rad9 CAD region and Chk1.
To address whether the interaction involving residues T125 and
T143 might require phosphorylation of these residues we studied
the Y2H interaction between Chk1 and aspartate mutants at
positions 125 and 143 in CADCDK1-9A. The negatively charged
aspartate residue is often used to mimic a phosphate. Substitution
of aspartate at residues 125 and 143 in CADCDK1-9A resulted in
interactions similar to those observed with threonines at these
positions, perhaps suggesting that these residues are phosphory-
lated (Figure S6E). We attempted to address this issue further by
measuring the Cdc28 dependency of the Y2H interaction using
the phospho-mimetic mutants, but these were unstable in the
absence of Cdc28 activity (Figure S6F).
As a direct and specific demonstration of the requirement for
phosphorylation of residues T125 and T143 in the Rad9/Chk1
interaction, we used 35 amino-acid peptides containing unmod-
ified, mono- or di-phosphorylated combinations of the residues to
pull down Chk1 (Figure 6B). Due to the low level of Chk1 that
interacts with Rad9 in extracts (Figure S5C and S5D), we used
affinity-purified Chk1-3FLAG from G2/M-arrested rad9D cells.
Peptides that contained phosphorylated T143 pulled Chk1 down
more efficiently than peptides lacking phosphorylation at this site
(compare T143p and T125pT143p with un-P and T125p in
Figure 6B). Lambda phosphatase treatment of the peptide
containing phosphorylated T143 reduced Chk1 interaction to
the level observed for the unphosphorylated peptide (compare
T143p, l and un-P in Figure 6B), which did not occur when
lambda phosphatase was inhibited (compare l and l+Inh in
Figure 6B), confirming the importance of T143 phosphorylation
for the interaction with Chk1.
Interestingly, we observed that peptides containing phosphor-
ylation of T125 displayed reduced Chk1 interaction, indepen-
dently of the phosphorylation status of T143, compared to
peptides containing unphosphorylated T125. This suggests that
phosphorylation of T125 has an inhibitory effect on the Rad9/
Chk1 interaction. We also noted that the stimulatory effect on the
interaction with Chk1 when T143 was phosphorylated was of
greater magnitude on the interaction than the inhibitory effect of
T125 phosphorylation. Taken together, the peptide pull-down
experiments suggest that phosphorylation of T143 is required for
efficient interaction with Chk1, while phosphorylation of T125 is
inhibitory for this interaction.
There is an apparent discrepancy between the Y2H analyses
and the peptide pull down experiments, as the former suggest that
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Figure 6. CDK sites 6 (T125) and 7 (T143) regulate the Rad9/Chk1 interaction. (A) The Y2H interaction between Rad9 and Chk1 mostly
requires the 6th and 7th CDK sites, T125 and T143, of the CAD region (B) Peptides pull down experiments identified phosphorylated T143 (CDK site 7)
and unphosphorylated T125 (CDK site 6) as the best combination of these sites required for maximum Chk1/Rad9 interaction. Chk1-3FLAG was
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the phospho-mimetic mutation at residue 125 allows interaction
with Chk1, while the latter indicates that phosphorylation of T125
is inhibitory. However, this discrepancy can be explained at least
in part by an obvious caveat of Y2H experiments, the considerable
overexpression of bait and prey proteins. Furthermore, Y2H
experiments cannot easily address the specific requirement of
phosphates at T125 and T143 because only a subpopulation of the
overexpressed proteins may be phosphorylated and weak residual
interactions independent of phosphorylation may be enhanced by
overexpression. Moreover, phospho-mimetic mutations do not
always mimic the effects of phosphorylated residues and can also
be subject to overexpression artefacts.
The peptide pull down experiments suggested that phosphor-
ylation of both T125 and T143 are key to controlling the
interaction between Rad9 and Chk1, therefore we investigated
whether these residues are phosphorylated in vitro and in vivo. We
first established whether Cdc28 phosphorylates Rad9 residues
T125 and T143 in vitro. To do this we used the purified Cdc28/
Clb2 complex on a peptide scanning array corresponding to the
Rad9 N-terminus (Figure 6C). The array consists of a library of 83
overlapping 19 mer peptides (Table S5) scanning across Rad9
residues 1–260 spot-synthesized onto nitrocellulose membranes.
Cdc28/Clb2 phosphorylated a number of control peptides
belonging to known Cdc28 targets (Figure 6C, see spots D1 to
D9) to a much greater extent than peptides belonging to reported
targets of either CK2 (spots D10 to D14) or Cdc7 kinases (spots
D16 to D19). Cdc28/Clb2 was not able to phosphorylate any of
the peptides containing the first five consensus CDK sites of Rad9
in this in vitro assay but could phosphorylate the Rad9 peptides
containing T125 and T218, as well as T143 and to a lesser extent
T155. This suggests that T125 and T143 are potential targets of
the Cdc28/Clb2 kinase.
To determine whether T125 and T143 can be phosphorylated
in vivo, we purified Rad9 from asynchronously growing cells and
G1 or G2/M arrested cells (Figure S7A). Samples were treated
with proteases and the resulting peptides were analyzed by mass
spectrometry (Table S1). Tandem mass spectra obtained by either
collision-activated dissociation or electron transfer dissociation of
peptides from the CAD region of Rad9 provided clear evidence
for phosphorylation in vivo on both T125 and T143 (Figure 6D,
Table S1, Figure S7B), two residues not previously reported as
phosphorylation sites [45–47]. Phosphorylation was also detected
on the known sites, S11, S26, S56, S83, S137, T155, and T218
(Figure 6D, Table S1) [45–47]. In G1 arrested cells, six of the
consensus Rad9 CDK sites (S11, S26, S56, S83, T125 and T218)
were found to be phosphorylated. Increased levels of phosphor-
ylation were detected on several of these sites on peptides from
G2/M arrested cells (Figure 6D, Table S1). Near stoichiometric
levels of phosphorylation were observed on peptides containing
T125 for asynchronous, G1- and G2/M arrested cells. In contrast,
phosphorylation levels observed for T143 containing peptides
ranged from 1–5% in all three of the above samples.
Taken together, our results are consistent with Cdc28-depen-
dent phosphorylation of T125 and T143 in the Rad9 CAD region.
Phosphorylation of T143 appears to facilitate the Rad9/Chk1
interaction whereas phosphorylation of T125 is inhibitory. The
combination of low levels of a stimulatory phosphorylation at
T143 and high level of an inhibitory phosphorylation at T125
would function to limit the basal pool of Rad9 that can interact
with Chk1.
Discussion
Complex cell cycle phosphorylation of Rad9 by Cdc28/
Clb complexes
We show that the S. cerevisiae Rad9 DNA damage response
mediator undergoes a complex pattern of phosphorylation during
the cell cycle. Both the cell cycle specificity of modification and
genetic evidence implicate Clb1-6 B-type cyclin forms of Cdc28 in
this regulation (Figure 1). The in vivo evidence demonstrating
Cdc28/Clb-dependent phosphorylation of Rad9 by Clb1-6 forms
of Cdc28 is supported by previous in vitro studies demonstrating
phosphorylation of Rad9 by purified Cdc28/Clb5 and Cdc28/
Clb2 complexes [44]. It is likely that all forms of Cdc28/Clb
complexes contribute to Rad9 cell cycle phosphorylation, switch-
ing from Clb5 and 6, followed by Clb3 and 4 and finally Clb1 and
2 as cells traverse the S, G2 and M phases. In vitro kinase assays
demonstrated that the phosphorylation of the N-terminal 250
amino acid region of Rad9 was mostly dependent on Cdc28/Clb2
complexes (Figure 2B), suggesting that this form of the kinase
might also be more specific for this N-terminal region. However,
although less than observed in G2/M arrested cells, significant
phosphorylation of Rad9 N-terminus was also detected in extracts
from G1 arrested cells (Figure 6D), which have extremely low Clb-
dependent kinase activity, suggesting that other kinases also
contribute to phosphorylation. Our results are inconsistent with a
simple threshold model of phosphorylation for regulation of the N-
terminal region. They suggest either that phosphorylation of some
of these sites is irrelevant or redundant to Rad9 function or,
consistent with our findings for the role of Rad9 in Chk1
activation, that specific combinations of phosphorylated or un-
phosphorylated CDK sites may regulate specific functions.
DDR mediators from higher cells such as 53BP1, BRCA1 and
MDC1 are also rich in consensus CDK sites and some of these
have been identified as sites of phosphorylation in vivo. It is likely
that modulation of the DDR by CDK-dependent phosphorylation
of mediators is evolutionarily conserved. For example, CDK-
dependent phosphorylation of S379 of mouse 53Bp1 is required
for binding to the mitotic kinase Plk1 [63], and S1497 of human
BRCA1 is needed for its subcellular localization [40].
immunopurified from rad9D cell clarified crude extracts (CCE) and incubated with four different biotinylated 35 amino-acid peptides. As represented
in red, the T125 T143, T125p, T143p and T125p143p peptides were un-, mono- or di-phosphorylated on residues T125 and T143. Magnetic
streptavidin beads were boiled to analyse both the presence of Chk1-3FLAG (anti-FLAG western blot) and that equal amount of peptides were used
in each pull down (see Ponceau S stain). The dependency on the phosphorylation of T143 was confirmed by lambda phosphatase treatment in the
absence (l) or in the presence of phosphatase inhibitors (l+Inh). Empty lanes are indicated by ‘x’ above the relevant lanes. (C) The Rad9 CAD peptide
array phosphorylation profile shows that peptides containing consensus CDK sites 6 (T125), 7 (T143), 8 (T155) and 9 (T218) are phosphorylated by
Cdc28/Clb2 in vitro. Peptides arrays of immobilized overlapping 19-mer peptides, each shifted to the right by 3 amino acids encompassing the first
260 amino acids of Rad9 sequence, were generated and are schematically represented at the top of the panel. The arrays were used in a kinase assay
with (+) or without (2) the purified Cdc28/Clb2 complex. Target peptides of Cdc28, CK2 and Cdc7 were also spotted as controls as indicated. (D)
Phosphorylation levels for CDK site-containing peptides within Rad9 isolated from asynchronous, G1- and G2/M arrested cells. Relative abundances
were determined by mass spectrometry (see Material and Methods section). Residues T125 and T143 (CDK sites 6 and 7 respectively) are differentially
phosphorylated in vivo. # indicates phosphorylated peptide containing this CDK site is assigned by HPLC retention time and accurate mass only.
ND=Not detected. Non-phosphorylated and phosphorylated peptides were not detected. See also Figure S7, Table S1 and Table S5.
doi:10.1371/journal.pgen.1003310.g006
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Chk1 activation is dependent on Cdc28 phosphorylation
of Rad9 in G2/M cells
The first 250 amino acids of Rad9, just under a fifth of the total
protein, contain half of its consensus CDK sites as well as the
previously identified Chk1 Activation Domain [35]. The molec-
ular mechanisms by which the Rad9 CAD region activates Chk1
were not previously determined. Here, we establish that the 9
CDK sites located in the Rad9 N-terminal CAD region are targets
for phosphorylation by Cdc28/Clb2. We also demonstrate that
these 9 sites are specifically required for Chk1 activation in
response to DNA damage, but not for Rad53 activation.
Consistent with a role for these CDK sites, Cdc28 is also required
for Chk1 activation in response to multiple DNA damaging agents
including those that cause DSBs or bulky lesions repairable by
nucleotide excision repair. Unlike DSB specific activation of
Rad53, Chk1 regulation cannot simply be a downstream
consequence of the involvement of Cdc28 in regulating DSB
specific responses such as DSBs resection [64,65] or the reported
Cdc28-dependent role for Rad9 in the inhibition of ssDNA
generation at DNA ends [66].
The mechanism by which CDK site phosphorylation of the
Rad9 CAD region regulates Chk1 involves a direct physical
interaction between the CAD region and Chk1. Surprisingly, Y2H
analyses suggest that the Rad9/Chk1 interaction detected in G1
cells also requires interaction of the CDK1-9 sites with Chk1.
However, in G1 cells the Y2H interaction between Rad9 and
Chk1 does not require Cdc28 activity and might even be
independent of phosphorylation. Taken together, our results
establish that in G2/M cells when Cdc28/Clb kinases are most
active Cdc28-dependent phosphorylation of CDK sites in the
CAD region of Rad9 acts to regulate the activation of Chk1 via its
interaction with Rad9.
Residues T125 and T143 reciprocally regulate the Chk1/
Rad9 interaction
While other residues in the Rad9 CAD domain may perform
regulatory roles (e.g. serine 11 implicated in the Rad9 and Dpb11
interaction [58]), our Y2H analyses point to T125 and T143 as
key residues for the interaction between Rad9 and Chk1.
Specifically, reintroduction of the T125 and T143 wild-type
residues into the nine alanine mutant (CADCDK1-9A) restored the
interaction between Rad9 and Chk1. Similarly, the introduction of
a negative charge at these positions using aspartate substitutions,
that may mimic phosphorylation, is also permissive for the Rad9/
Chk1 interaction. Conversely, a mutant where both these residues
were substituted to alanine in an otherwise wild-type Rad9
sequence was defective for the Rad9/Chk1 interaction. Thus
T125 and T143 are part of a Rad9/Chk1 interaction module,
which can tolerate substitution to aspartate but not alanine. We
directly assessed the consequence of the phosphorylation status of
T125 and T143 on their ability to interact with Chk1 using
peptide-pull down experiments. Interestingly, we found that
phosphorylation of T143 stimulates the Rad9/Chk1 interaction,
whereas phosphorylation of T125 is inhibitory to this interaction.
Importantly, we have established that these two residues are
phosphorylated not just in vitro but also in vivo. While T125 is a
major site of phosphorylation, T143 is only a minor site of
phosphorylation. The dual regulation of the Rad9/Chk1 interac-
tion by these residues, where the optimal configuration is
phosphorylation of T143 but not T125, would ensure only a
small proportion of Rad9 molecules interact with Chk1. This is
consistent with our observations using immunoprecipitation where
we find that most Rad9 molecules are not bound to Chk1 and can
form other complexes that do not contain Chk1. Dual regulation
of Rad9 by phosphorylating T143 and dephosphorylating T125
may also fine-tune Rad9/Chk1 complex formation in response to
DNA damage. For example, regulated de-phosphorylation of
T125 by a specific phosphatase-containing complex associated to
phosphorylation of T143 could be used to enforce or maintain
Chk1 signalling subsequent to the initial activating event. The
ability to manipulate the Rad9/Chk1 interaction with stimulatory
and inhibitory phosphorylation events provides interesting possible
mechanisms for its temporal and/or spatial regulation. Taken
together, our results indicate that T125 and T143 constitute
important components of the interaction surface on Rad9 that
binds to Chk1, in which phosphorylation of these residues
contributes either negatively of positively respectively to the
docking of Chk1 onto the Chk1 Activating Domain of Rad9.
Molecular mechanism regulating Chk1 activation
Our results are consistent with a novel model for Chk1
activation (Figure 7). The Rad9/Chk1 interaction is DNA
damage-independent but regulated during S/G2/M by Cdc28/
Clb-dependent modification of Rad9 (Figure 7A). The Rad9/
Chk1 interaction is very likely to be most stimulated when T143
is phosphorylated and T125 is unphosphorylated (Figure 7B).
Rad9 and Chk1 are both believed to dynamically associate with
chromatin even in the absence of DNA damage [58,67,68]. Rad9
complexes undergo enhanced chromatin recruitment in the
vicinity of damaged DNA by exposure to or generation of specific
histone marks such as H3K79me2 and cH2A [67,69]. Other sites
of phosphorylation in Rad9 are involved in its recruitment to
Dpb11, which is recruited in a 9-1-1 complex-dependent manner
[60] (Figure 7C). The Rad9/Dpb11 interaction can be either
direct via Rad9 T462 and T474 [70] or indirect via Rad9 S11
[58]. Together, the 9-1-1 and Dpb11 complexes enhance the
kinase activity of Mec1 bound to RPA-coated ssDNA in a
mechanism that is conserved from yeast to human cells [59].
Mec1 kinase activity at sites of DNA damage results in DNA
damage-dependent phosphorylation and remodelling of both
Rad9 [25] and Chk1 [29], which in turn leads to in cis
autophosphorylation of Chk1 [31] and subsequent release of
the D-Rad9/Chk1 complex from damaged chromatin
(Figure 7D). The Rad9/Chk1 complex is a constitutive but
minor Rad9 complex. It is recruited along with other Rad9
complexes to sites of DNA damage where Rad9 is converted from
its C- to D-form, irrespective of its interaction with Chk1. Thus,
after DNA damage Chk1 interacts specifically with D-Rad9.
Interestingly, activation of the Chk1 kinase contrasts with Rad53
(also known as Chk2) activation which involves its in trans auto-
phosphorylation subsequent to Mec1 (ATR)-dependent priming
and its specific interaction with D-Rad9 generated in response to
DNA damage [27]. Additionally, in vitro experiments suggest that
activated Rad53 is released from Rad9 in an ATP-dependent
mechanism [26] which we did not observe with Chk1. Release of
Chk1 from Rad9 could be controlled by the reversal of the
phosphorylation status of residues T125 and T143. Alternatively,
it could also be controlled by the de-phosphorylation of PIK
kinase-dependent sites of phosphorylation on Chk1 at a later
stage of the response as has been reported for human Chk1 [30].
While our findings predict that de-phosphorylation of T143 and
phosphorylation of T125 would destabilise the interaction
between Rad9 and Chk1, the maintenance of T143 phosphor-
ylation and lack of T125 phosphorylation could keep the Rad9/
Chk1 interaction intact in the proximity of damaged chromatin
where activated Chk1 could then phosphorylate local targets.
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Conservation of Chk1 activation mechanisms
Together with a recent report [71], our work constitutes the first
detailed characterisation of Chk1 activation in the major yeast
model systems. The fission yeast homologue of Rad9, Crb2
interacts with Chk1 through a Chk1-binding module that also
involves two N-terminally located phosphorylated residues, T73
and S80 [71]. However, these residues are not conserved in Rad9
and are not sites of CDK-dependent phosphorylation. Instead
phosphorylation of Crb2 residues T73 and S80 is dependent upon
DNA damage and Rad3, the Mec1/ATR homologue in fission
yeast [71]. Interestingly, the principal role for Crb2 and Rad9 in
Chk1 activation, its recruitment to sites of DNA damage to allow
its activation by PIKKs, is conserved between budding and fission
yeasts. However, the two yeasts achieve this role by divergent
mechanisms. Fission yeast Crb2 is using a DNA damage-
recruitment mechanism stimulated by Rad3-phosphorylated
docking sites. In contrast, in budding yeast the constitutive Rad9
sub-complex is found in cycling cells that have not been subject to
exogenous DNA damage and both Rad9 and Chk1 are co-
recruited on damaged chromatin.
It is possible that the differences between Chk1 regulation in
budding and fission yeast reflect the difference in regulating the
cell cycle in the two yeasts. Budding yeast has a clearly defined G1
phase, whereas fission yeast normally does not. It is also possible
that the DNA damage-independent Rad9/Chk1 interaction
indicates a yet unidentified role for this complex in the absence
of DNA damage. Alternatively, or perhaps in addition, budding
yeast regulation of the Rad9/Chk1 interaction might reflect the
more discrete and specific roles of S. cerevisiae Chk1 kinase in
checkpoint regulation and the need to limit Chk1 activation to its
specific contexts. In contrast, S. pombe Chk1 is the main DNA
damage checkpoint kinase, fulfilling roles equivalent to that of the
Rad53 kinase in budding yeast, and, therefore, Rad3-dependent
regulation of the Crb2/Chk1 interaction might allow a less
restricted activation of the S. pombe kinase. Even further complexity
in the regulation of Chk1 activity is suggested by the regulation of
the Claspin/Chk1 interaction by the constitutively active Casein
kinase 1 gamma 1 in human cells [72]. Nevertheless, Chk1
recruitment to sites of DNA damage is conserved from yeast to
human cells, since recruitment of DNA damage mediators to
Figure 7. Model of Chk1 activation in response to DNA damage. Note that the tetramer representation of Rad9 is a possible conformation for
the C-Rad9 oligomeric complex of greater than or equal to 850 kDa, which is remodelled into a smaller complex of approximately 560 kDa containing
D-Rad9 after DNA damage. See text for a description of the model.
doi:10.1371/journal.pgen.1003310.g007
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damaged chromatin is dependent upon the Mec1/Rad3/ATR
kinases [24].
In higher cells, the role played by DDR mediator proteins is
more complex than in yeasts as multiple mediators are known and
their molecular mechanisms in checkpoint activation remain
largely uncharacterised [4,32]. Among human mediators, Claspin-
dependent activation of CHK1 is best characterized, although
BRCA1 and MDC1 also play undefined roles in this activation.
Our work suggests that activation of human CHK1 by mediator
proteins, possibly those related to budding yeast Rad9, may also be
integrated into cell cycle stage by their prior CDK-dependent
phosphorylation and dynamic interaction with CHK1. Cell cycle-
dependent phosphorylation may also fine-tune other functions of
mediator proteins.
Materials and Methods
Strains
All strains used in this work are listed in Table S2 and in the
W303 background (MATa ade2-1 trp1-1 can1-100 leu2-3,12 his3-
11,15 ura3) with the exception of CG378 used in Figure 1A and
strains used to purify the Cdc28 complexes. All mutant and tagged
alleles used were integrated on the chromosome apart from the
yeast two-hybrid experiments. Yeast strain (Table S2) and plasmid
constructions (Text S1) are described in supplementary material.
Plasmids and oligonucleotides used in this study are listed in
Tables S3 and S4.
Cell cycle arrest and checkpoint experiments
These experiments were performed as described earlier [11]
and are described in detail in supplemental methods (Text S1).
Antibodies
Western blotting was performed as previously described [11,20].
Rad9 phosphoforms, Rad53, Swi6, Dpb11-13MYC, RAD9-
9MYC and Chk1-3FLAG were probed with NLO5 and NLO16
[11,20] or Abcam anti-Rad53 (ab104232), NLO2 (D. Lee & N.
Lowndes), anti-MYC (9E11, Abcam) and anti-FLAG (M2, Sigma)
antibodies respectively. Sic1, Clb2, Chk1-3HA, CAD-HA and
Orc6 were with anti-Sic1 (JD156 from J. Diffley), anti-Clb2
(sc9071 from Santa Crutz), anti-HA (12CA5) and anti-Orc6 (SB49
from B. Stillman) antibodies respectively.
In vitro kinase assay using specific Cdc28 complexes
The purification of the four Cdc28 complexes and the in vitro
kinase assays were performed as described previously [55].
Yeast two-hybrid
Interactions were assessed using Clontech Matchmaker TM
Gold Yeast Two Hybrid System (Catalog no 630489) according to
the manufacturer’s instructions. A triple-plasmid based assay was
used to study the Cdc28-dependent interaction between Rad9 and
Chk1 proteins as described earlier [58].
Yeast native extracts and immunoprecipitations
Clarified crude extracts (CCE) of wild type or rad9CDK1-9A cells,
expressing either both Chk1-3FLAG and Rad9-9MYC or both
Chk1-3FLAG and Dpb11-13MYC, arrested in G2/M phase and
either mock treated or treated with 20 mg/ml of bleocin
(Calbiochem) for 45 min were generated as previously described
[58]. One ml of CCE at a concentration of 10 mg/ml was used in
immunoprecipitation experiments as previously described [58]
with anti-FLAG, anti-MYC or IgG antibodies. Beads were finally
resuspended in 40 ml of 36Laemmli buffer, boiled for 5 min and
released proteins were separated on SDS-PAGE gels for western
blot analysis. Note that all tagged strains were confirmed for
functionality (Figure S7C).
Peptide pull-down experiment
Chk1-3FLAG was immunopurified from rad9D cell crude
extracts as described in supplementary material. Biotin-labelled
Rad9 peptides, synthetised by Pepceuticals Limited (Leicester-
shire, UK), were used to saturate pre-washed Streptavidin
Dynabeads M-280 (Invitrogen). In experiment involving phos-
phatase treatment, peptides beads were treated with 10 unit of l
phosphatase for 20 min at 30uC in the presence or in the
absence of phosphatase inhibitors. Immunopurified Chk1-
3FLAG was added to the peptides beads and incubated for
2 hours, on a rotating wheel at 4uC. The washed beads were
resuspended in sample buffer, boiled at 95uC, loaded onto a 20%
SDS-PAGE gel for peptide detection by Ponceau staining or on a
6.5% 80/1 acrylamide/bis-acrylamide SDS-PAGE gel to visu-
alize Chk1-3FLAG.
SPOT synthesis of peptides and array experiment
The peptides arrays of Rad9 on nitrocellulose were generated as
previously described [73]. Essentially, scanning libraries of
overlapping 19-mer peptides covering the 260 first amino-acids
of Rad9 (listed in Table S5) were produced by automatic SPOT
synthesis and synthesized on continuous cellulose membrane
supports on Whatman 50 cellulose using Fmoc (9-fluorenylmethy-
loxycarbonyl) chemistry with the AutoSpot-Rosbot ASS 222
(Intavis Bioanalytical Instruments). Peptide arrays were submitted
to Cdc28/Clb2 kinase assays.
Rad9 mass spectrometry analysis
A two-step immunopurification of Rad9-GFP-FLAG was
performed on crude cell extracts obtained from asynchronous,
G1- and G2/M arrested cells (Text S1). Peptides from purified
Rad9-GFP-FLAG protein were analyzed by collision-activated
dissociation and/or electron transfer dissociation tandem mass
spectrometry (Text S1). Phosphopeptides detected from the CAD
region of Rad9 are presented in Table S1. Percent relative
abundances for the Rad9 phosphopeptides were calculated from
the ion currents observed in main beam mass spectra [(phosphor-
ylated peptide ion current)/(phosphorylated peptide+non- phos-
phorylated peptide ion current)6(100)]. Phosphorylation sites were
assigned by manual interpretation of collision-activated dissocia-
tion and/or electron transfer dissociation tandem mass spectra
obtained for each phosphopeptide species. All phospho-peptide
signals were detected at signal/noise levels greater than 100 (S/
N=.100).
Supporting Information
Figure S1 Related to Figure 1. Cell cycle phosphorylation of
Rad9 is not dependent on DNA replication structures but on
multiple potential CDK phosphorylation sites in Rad9. (A) Rad9 is
phosphorylated in asynchronous cells in absence of DNA damage.
The slow migrating forms of Rad9 caused by cell cycle
phosphorylation disappear in response to l phosphatase treat-
ment. (B) Rad9 phosphorylation is independent from the initiation
of DNA synthesis. Cell cycle phosphorylation of Rad9 was
examined in a cell cycle engineered to bypass S phase, by
manipulating the level of the Cdc6 replication protein. In the
absence of Cdc6 cells undergo a haploid mitosis in which the
monovalent chromosomes are randomly segregated to either pole.
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Cells in which Cdc6 was either present or absent were released
from a late mitotic block (the cdc15-22 mutation at 36uC) [74] and
examined for Rad9 cell cycle phosphorylation and progression
through the cell cycle. Rad9 was normally phosphorylated
irrespective of whether DNA synthesis took place or not. Thus,
although Rad9 phosphorylation during cell cycle progression is
dependent upon Cdc28/Clbs complexes, it is independent of
DNA structures generated during a normal S phase.
(EPS)
Figure S2 Related to Figure 2. The CDK1-9 sites within the
CAD region of Rad9 are phosphorylated both in vitro and in vivo. (A)
Silver-stained gel of the purified Cdc28/Cln complexes used in this
study. * indicates a contaminant in the Cdc28/Cln2 purification. (B)
Cdc28/Clb2 phosphorylates Rad9 CADWT but not CADCDK1-9A in
vitro. In vitro kinase assays were performed on the indicated substrates
with higher concentration of Cdc28/Clb2 complex than the one
presented in Figure 5D (3.6 nM compared to 0.6 nM). * indicates
degradation product of Rad9 CADWT. (C) Cells expressing
Rad9CDK1-9A as their only Rad9 protein are not sensitive to the
indicated DNA damaging treatments. Drop tests were performed in
the indicated strains. Note that the bleocin sensitivity of proliferating
chk1D cells could indicate a role for CHK1 in surviving bleocin-
induced lesions during S phase, which can be rescued by a transient
arrest at the G2/M transition induced on nocodazole plates. This
role is clearly independent from the N terminus of Rad9. (D)
Rad9CDK1-9A displays defective cell cycle and Cdc28-dependent
phosphorylation in vivo. Rad9 western blot prepared from the
indicated strains. Rad912A is the short name of a strain expressing
rad9CDK1,3,4,6,9,11,14,16-20A (Karen Finn, Unpublished data). 1-
NMPP1 treatment of cdc28-as1 cells was used to indicate Cdc28-
dependent phosphorylation. (E) DNA damage-induced Chk1
phosphorylation is defective in rad9CDK1-9A, rad9CADD and rad9 D
cells. Asynchronously growing cells were treated with 4-NQO for
the indicated times and Chk1 phosphorylation analysed by western
blotting. (F) IR, 4-NQO or UV-induced Chk1 phosphorylation is
abolished in nocodazole arrested rad9CDK1-9A, rad9CAD and rad9D
cells, but there is residual Chk1 activation partially dependent on
the CDK1-9 sites in G1-arrested cells.
(TIF)
Figure S3 Related to Figure 3. The CDK1-9 sites within the
CAD region of Rad9 are not required for damage-induced Rad9
and Rad53 phosphorylations. (A) Rad9 DNA damage-induced
phosphorylation is not dependent on the CDK1-9 sites in G2/M-
arrested cells after IR and in asynchronously growing cells after 4-
NQO. (B) Rad53 DNA damage-induced phosphorylation is not
dependent on the CDK1-9 sites in G2/M-arrested cells after IR or
4-NQO and in asynchronous cells after 4-NQO.
(TIF)
Figure S4 Related to Figure 4. Cdc28 activity is required for
initiation and maintenance of DNA damage-induced Chk1
activation in G2/M cells. (A) CDK-dependency of the initial IR
(+400 Gy) induced phosphorylation of Chk1. Cdc28 was inacti-
vated with 1-NMPP-1 in half of the G2 arrested cells and treated
with IR to initiate the checkpoint in populations with and without
Cdc28 activity. Protein samples were collected at the indicated
time points and Chk1 phosphorylation analysis was performed.
Orc6 phosphorylation is used as a control for Cdc28 inactivation
in all experiments. (B) CDK-dependency of the maintenance of
bleocin- induced Chk1 phosphorylation. 1-NMPP1 was added
into half of the G2/M arrested and bleocin-treated cells to
inactivate Cdc28 activity. Chk1 phosphorylation analysis was
performed from protein extracts collected at the indicated time
points. Cdc28 activity was regulated using the 1-NMPP1 inhibitor
in G2/M arrested cdc28-as1 cells treated with bleocin or 4-NQO
to examine the maintenance of Chk1 signaling. Rad9 and Rad53
were followed as markers of checkpoint activation. (C) CDK-
dependency of the maintenance of IR (+400 Gy) induced Chk1
phosphorylation. 1-NMPP1 was added into half of the G2/M
arrested and IR-treated cells to inactivate Cdc28 activity. Chk1
phosphorylation analysis was performed from protein extracts
collected at the indicated time points.
(EPS)
Figure S5 Related to Figure 5. Interaction between Rad9 and
Chk1 is dependent on the Rad9 CDK1-9 sites. (A) The Y2H
interaction between Rad9 and Chk1 is dependent on the CDK1-9
sites in both G1 and G2/M cells. The indicated bait and prey
plasmids introduced into Y2H cells (identical to clones shown in
S5A) were grown, divided into two flasks and arrested in G2/M
and G1 phases of cell cycle. 1 ml of cells corresponding to one OD
value were used to perform the PNP assay (see supplementary
information). The a-galactosidase activity was measured according
to Clontech Yeast Two Hybrid instructions. (B) Western blotting
analysis of the indicated proteins in a reciprocal IP using Rad9-
9MYC and Chk1-3FLAG expressing cells confirms the Rad9 and
Chk1 interaction. Anti-MYC antibodies were used with extracts
from nocodazole-arrested cells, treated with 20 mg/ml of bleocin
for 45 min and a mock (IgG) control was performed. Rad9
binding to Rad53 was used as a further control. Different
exposures of the crude extracts and the IPs lanes are shown to
allow visualization of Rad9-9MYC, Chk1-3FLAG and Rad53
specific bands. (C) Western blotting analysis of the supernatants
resulting from the IP experiment using Chk1-3FLAG and Dpb11-
13MYC expressing cells presented in Figure 5C. (D) Western
botting analysis of the supernatants resulting from IP experiment
using Rad9-9MYC and Chk1-3FLAG expressing cells presented
in Figure S5B. (E) ATP-dependent release of Rad53, but not Chk1
from Rad9 IPs. Assays were performed as described (Gilbert et al,
2001) except Rad9-9MYC was immunoprecipitated using an anti-
MYC monoclonal antibody. The extract was prepared from
nocodazole-arrested cells, treated with 20 mg/ml of bleocin for
45 min that expressed both Rad9-9MYC and Chk1-3FLAG. The
amount of Rad9-9MYC, Chk1-3FLAG or Rad53 remaining on
the beads (Beads) or released (Elution) after incubation with ATP
(+), ATP-cS (cS), a non-hydrolysable analogue, or mock treatment
without any nucleotide (2) was determined by western blotting.
Different exposures of the crude extracts, elutions and beads lanes
are shown to allow visualization of Rad9, Chk1 and Rad53
specific bands. N indicates the signal detected from the IgG heavy
chains.
(TIF)
Figure S6 Related to Figure 6. T125 and T143 are important
for Rad9/Chk1 interaction. (A) Schematic representation of the
different combinations of mutated CDK sites in the CAD region of
Rad9. (B) IR-induced Chk1 activation analysis in rad9CDK
intermediate mutants shown in (A) covering all the sites in the
CAD region. The single consensus PIK site (T16/A) in the CAD
region was also tested (in rad9CDK1,2,PIK1A mutant) for IR-induced
Chk1 phosphorylation, but had no effect. G2/M arrested wild
type and mutants were treated with IR and cells were collected
after 30 minutes for budding index and western blot analysis. (C)
The Y2H interaction between Rad9 CAD and Chk1 is restored by
the reversion to a wild-type residue of the alanine mutation of the
6th and 7th CDK sites (T125 and T143 respectively) in the
CADCDK1-9A mutant. The analysis of the CADCDK1-9A+6T,
CADCDK1-9A+7T and CADCDK1-9A+6T7T (labelled 6T, 7T and
6T7T) shows that the two residues do not contribute additively to
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this Y2H interaction. (D) The Y2H interaction between Rad9
CAD and Chk1 is affected when both the 6th and 7th CDK sites,
T125 and T143 respectively, are mutated to alanine a non-
phosphorylatable residue. Note that all the other consensus sites
are wild type in the 6A7A (CADCDK6A+7A) mutant. (E) The Y2H
interaction between Rad9 CAD and Chk1 is restored by the
reversion of the alanine mutation of both the 6th and 7th CDK
sites, T125 and T143 respectively, to aspartate, a phosphomimetic
residue in the CADCDK1-9Amutant. The mutants CADCDK1-
9A+6D, CADCDK1-9A+7D and CADCDK1-9A+6D7D are labelled 6D,
7D and 6D7D. Note that the 7D and 6D7D mutants restore the
interaction to the same extent as the 6T7T (CADCDK1-9A+6T7)
wild type residue reversion. (F) The Rad9 CAD region
overexpressed in the Y2H triple plasmid based assay is unstable
when Cdc28 is inactivated. Interaction between Rad9 CAD,
CADCDK1-9A, CADCDK1-9A+6T or CADCDK1-9A+7T (labelled WT,
1-9A, 6T and 7T respectively) and Chk1 has been quantified in
cdc28-as1 cells arrested in G2/M and treated with NMPP1 (Cdc28
2) or not (Cdc28 +). Over-production of the CAD regions was
detected by Western blot analysis and is shown in the bottom
panel.
(EPS)
Figure S7 In vivo analysis of Rad9 Chk1 Activation Domain
phosphorylation status. (A) Silver stained gel of the purified Rad9-
GFP-FLAG used in ETD-Mass spectrometry analyses shown in
Figure 6D and Table S1. This gel shows the result of the second
immunopurification step (GFP) described in supplemental meth-
ods. The Flag elution (Load) was incubated with GFP-Trap beads.
The Rad9-GFP-FLAG retained on these beads (Beads) was used
for the analyses. The unbound fraction (FT) shows the presence of
two unspecific high molecular weight bands not detected in Rad9
western blotting. (B) Extracted Ion Chromatograms (XIC) and
Main Beam Mass Spectra (MS) obtained for the T143-containing
Rad9 peptides isolated from G2-arrested cells (YQSS-
DLEDTPLMLRK – Top Panel and YQSSDLEDpTPLMLRK
– Bottom Panel). Signal to noise levels for this phosphopeptide and
all others in Table S1 are .100 (S/N=.100). (C) Drop test
analysis of the indicated tagged strains used for immunoprecip-
itation experiments shown in Figure 5 and Rad9 purification used
for mass spectrometry analyses in Figure 6D, Table S1 and Figure
S7A and B. Note that these strains are not sensitive to DNA
damaging treatments.
(TIF)
Table S1 Rad9, Chk1 activation domain phosphorylation sites
assigned by manual interpretation of collision-activated dissocia-
tion and/or electron transfer dissociation mass spectra.
a Phosphopeptide levels are reported as % total peptide abundance
detected, (++++) = 70–100%, (+++) 35–69%, (++) = 6–34%,
(+) = 1–5%, (2) no phosphorylated peptide detected. % Total
abundances were calculated from ion currents observed in the
main beam mass spectra [(phosphorylated peptide ion current)/
(phosphorylated peptide+non-phosphorylated peptide ion cur-
rent)6(100)]. b Phosphorylated peptide containing this phosphor-
ylation site was assigned by HPLC retention time and correct
accurate mass, only. c ND=Not detected. Non-phosphorylated
and phosphorylated peptides were not detected.
(DOCX)
Table S2 Strains used in this study.
(DOCX)
Table S3 Plasmids used in this study.
(DOCX)
Table S4 Primers used in this study.
(DOCX)
Table S5 Amino acid sequences of the peptides used in array.
Peptides arrays of immobilized overlapping 19-mer peptides, each
shifted to the right by 3 amino acids encompassing the entire Rad9
CAD sequence were generated. At position A1, we included amino
acids 2–20 of Rad9 (i.e. without starting Methionine). For the
control peptides, we used peptides containing target sites for Cdc28
(D1 to D9), CK2 (D11 to D15) and Cdc7 kinases (D17 to D20).
(DOCX)
Text S1 Supplemental description of material and methods used
in this study.
(DOC)
Acknowledgments
The authors thank J. Vialard, S. Healy, D. Lee, J. Soulier, A.
O’Shaugnessy, and E. Bosneaga for early contributions leading to this
manuscript; E. Glancy for technical assistance; J. Diffley, D. Lydall, M.
Muzzi-Falconi, A. Peliciolli, P. Plevani, K. Shokat, B. Stillman, and W.
Zachariae for strains, plasmids, chemicals, and antibodies; M. Ko˜ivoma¨gi
and M. Loog for recombinant proteins, strains, detailed advice, and helpful
discussion on the Cdc28 complexes specificity in vitro analyses; and A.
Flaus, C. Morrison, C. Santocanale, and V. Smits for critical reading of the
manuscript.
This work is dedicated to Mary Thornton.
Author Contributions
Conceived and designed the experiments: MG NFL. Performed the
experiments: CMA RK DH KC SE AWD MG NFL. Analyzed the data:
CMA RK AWD DH KC JS DFH MG NFL. Contributed reagents/
materials/analysis tools: RK CMA DH AWD KC KF JLB JS RO PAK
DFH MG NFL. Wrote the paper: MG NFL. Contributed to conception
and design of experiments: CMA RK AWD KF JLB JS DFH. Contributed
to manuscript writing: CMA RK AWD DFH.
References
1. Harper JW, Elledge SJ (2007) The DNA damage response: ten years after. Mol
Cell 28: 739–745.
2. Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA
damage model for cancer development. Science 319: 1352–1355.
3. Durocher D, Jackson SP (2001) DNA-PK, ATM and ATR as sensors of DNA
damage: variations on a theme? Curr Opin Cell Biol 13: 225–231.
4. Stracker TH, Usui T, Petrini JH (2009) Taking the time to make important
decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage
response. DNA Repair (Amst) 8: 1047–1054.
5. FitzGerald JE, Grenon M, Lowndes NF (2009) 53BP1: function and mechanisms
of focal recruitment. Biochem Soc Trans 37: 897–904.
6. Jungmichel S, Stucki M (2010) MDC1: The art of keeping things in focus.
Chromosoma 119: 337–349.
7. O’Donovan PJ, Livingston DM (2010) BRCA1 and BRCA2: breast/ovarian
cancer susceptibility gene products and participants in DNA double-strand break
repair. Carcinogenesis 31: 961–967.
8. Weinert TA, Hartwell LH (1988) The RAD9 gene controls the cell cycle
response to DNA damage in Saccharomyces cerevisiae. Science 241: 317–322.
9. Saka Y, Esashi F, Matsusaka T, Mochida S, Yanagida M (1997) Damage and
replication checkpoint control in fission yeast is ensured by interactions of Crb2,
a protein with BRCT motif, with Cut5 and Chk1. Genes Dev 11: 3387–3400.
10. Willson J, Wilson S, Warr N,Watts FZ (1997) Isolation and characterization of the
Schizosaccharomyces pombe rhp9 gene: a gene required for the DNA damage
checkpoint but not the replication checkpoint. Nucleic Acids Res 25: 2138–2146.
11. O’Shaughnessy AM, Grenon M, Gilbert C, Toh GW, Green CM, et al. (2006)
Multiple approaches to study S. cerevisiae Rad9, a prototypical checkpoint
protein. Methods Enzymol 409: 131–150.
12. Barbour L, Ball LG, Zhang K, Xiao W (2006) DNA damage checkpoints are
involved in postreplication repair. Genetics 174: 1789–1800.
13. de la Torre-Ruiz M, Lowndes NF (2000) The Saccharomyces cerevisiae DNA
damage checkpoint is required for efficient repair of double strand breaks by
non-homologous end joining. FEBS Lett 467: 311–315.
CDK Regulates Rad9/Chk1 Interaction
PLOS Genetics | www.plosgenetics.org 16 April 2013 | Volume 9 | Issue 4 | e1003310
14. Murakami-Sekimata A, Huang D, Piening BD, Bangur C, Paulovich AG (2010)
The Saccharomyces cerevisiae RAD9, RAD17 and RAD24 genes are required
for suppression of mutagenic post-replicative repair during chronic DNA
damage. DNA Repair (Amst) 9: 824–834.
15. Toh GW, O’Shaughnessy A M, Jimeno S, Dobbie IM, Grenon M, et al. (2006)
Histone H2A phosphorylation and H3 methylation are required for a novel
Rad9 DSB repair function following checkpoint activation. DNA Repair (Amst).
16. Cortez D, Wang Y, Qin J, Elledge SJ (1999) Requirement of ATM-dependent
phosphorylation of brca1 in the DNA damage response to double-strand breaks.
Science 286: 1162–1166.
17. Emili A (1998) MEC1-dependent phosphorylation of Rad9p in response to DNA
damage. Mol Cell 2: 183–189.
18. Lou Z, Minter-Dykhouse K, Wu X, Chen J (2003) MDC1 is coupled to
activated CHK2 in mammalian DNA damage response pathways. Nature 421:
957–961.
19. Rappold I, Iwabuchi K, Date T, Chen J (2001) Tumor suppressor p53 binding
protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol
153: 613–620.
20. Vialard JE, Gilbert CS, Green CM, Lowndes NF (1998) The budding yeast
Rad9 checkpoint protein is subjected to Mec1/Tel1-dependent hyperpho-
sphorylation and interacts with Rad53 after DNA damage. Embo J 17: 5679–
5688.
21. Xia Z, Morales JC, Dunphy WG, Carpenter PB (2001) Negative cell cycle
regulation and DNA damage-inducible phosphorylation of the BRCT protein
53BP1. J Biol Chem 276: 2708–2718.
22. Xu X, Stern DF (2003) NFBD1/KIAA0170 is a chromatin-associated protein
involved in DNA damage signaling pathways. J Biol Chem 278: 8795–8803.
23. Usui T, Foster SS, Petrini JH (2009) Maintenance of the DNA-damage
checkpoint requires DNA-damage-induced mediator protein oligomerization.
Mol Cell 33: 147–159.
24. Finn K, Lowndes NF, Grenon M (2012) Eukaryotic DNA damage checkpoint
activation in response to double-strand breaks. Cell Mol Life Sci 69: 1447–1473.
25. Gilbert CS, Bosch Mv M, Green CM, Vialard JE, Grenon M, et al. (2003) The
budding yeast Rad9 checkpoint complex: chaperone proteins are required for its
function. EMBO Rep 4: 953–958.
26. Gilbert CS, Green CM, Lowndes NF (2001) Budding yeast Rad9 is an ATP-
dependent Rad53 activating machine. Mol Cell 8: 129–136.
27. Pellicioli A, Foiani M (2005) Signal transduction: how rad53 kinase is activated.
Curr Biol 15: R769–771.
28. Goto H, Kariya R, Shimamoto M, Kudo E, Taura M, et al. (2012) Antitumor
effect of berberine against primary effusion lymphoma via inhibition of NF-
kappaB pathway. Cancer Sci 103: 775–781.
29. Tapia-Alveal C, Calonge TM, O’Connell MJ (2009) Regulation of chk1. Cell
Div 4: 8.
30. Kasahara K, Goto H, Enomoto M, Tomono Y, Kiyono T, et al. (2010) 14-3-
3gamma mediates Cdc25A proteolysis to block premature mitotic entry after
DNA damage. EMBO J 29: 2802–2812.
31. Chen Y, Caldwell JM, Pereira E, Baker RW, Sanchez Y (2009) ATRMec1
phosphorylation-independent activation of Chk1 in vivo. J Biol Chem 284: 182–
190.
32. Smits VA, Warmerdam DO, Martin Y, Freire R (2010) Mechanisms of ATR-
mediated checkpoint signalling. Front Biosci 15: 840–853.
33. Chen Y, Sanchez Y (2004) Chk1 in the DNA damage response: conserved roles
from yeasts to mammals. DNA Repair (Amst) 3: 1025–1032.
34. Tanaka K (2010) Multiple functions of the S-phase checkpoint mediator. Biosci
Biotechnol Biochem 74: 2367–2373.
35. Blankley RT, Lydall D (2004) A domain of Rad9 specifically required for
activation of Chk1 in budding yeast. J Cell Sci 117: 601–608.
36. Esashi F, Mochida S, Matsusaka T, Obara T, Ogawa A, et al. (2000)
Establishment of and recovery from damage checkpoint requires sequential
interactions of Crb2 with protein kinases Rad3, Chk1, and Cdc2. Cold Spring
Harb Symp Quant Biol 65: 443–449.
37. Wohlbold L, Fisher RP (2009) Behind the wheel and under the hood: functions
of cyclin-dependent kinases in response to DNA damage. DNA Repair (Amst) 8:
1018–1024.
38. Esashi F, Yanagida M (1999) Cdc2 phosphorylation of Crb2 is required for
reestablishing cell cycle progression after the damage checkpoint. Mol Cell 4:
167–174.
39. Jullien D, Vagnarelli P, Earnshaw WC, Adachi Y (2002) Kinetochore
localisation of the DNA damage response component 53BP1 during mitosis.
J Cell Sci 115: 71–79.
40. Ruffner H, Jiang W, Craig AG, Hunter T, Verma IM (1999) BRCA1 is
phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2
phosphorylation site. Mol Cell Biol 19: 4843–4854.
41. Ruffner H, Verma IM (1997) BRCA1 is a cell cycle-regulated nuclear
phosphoprotein. Proc Natl Acad Sci U S A 94: 7138–7143.
42. Moses AM, Heriche JK, Durbin R (2007) Clustering of phosphorylation site
recognition motifs can be exploited to predict the targets of cyclin-dependent
kinase. Genome Biol 8: R23.
43. Ubersax JA, Woodbury EL, Quang PN, Paraz M, Blethrow JD, et al. (2003)
Targets of the cyclin-dependent kinase Cdk1. Nature 425: 859–864.
44. Loog M, Morgan DO (2005) Cyclin specificity in the phosphorylation of cyclin-
dependent kinase substrates. Nature 434: 104–108.
45. Albuquerque CP, Smolka MB, Payne SH, Bafna V, Eng J, et al. (2008) A
multidimensional chromatography technology for in-depth phosphoproteome
analysis. Mol Cell Proteomics 7: 1389–1396.
46. Holt LJ, Tuch BB, Villen J, Johnson AD, Gygi SP, et al. (2009) Global analysis of
Cdk1 substrate phosphorylation sites provides insights into evolution. Science
325: 1682–1686.
47. Smolka MB, Albuquerque CP, Chen SH, Schmidt KH, Wei XX, et al. (2005)
Dynamic changes in protein-protein interaction and protein phosphorylation
probed with amine-reactive isotope tag. Mol Cell Proteomics 4: 1358–1369.
48. Grenon M, Gilbert C, Lowndes NF (2001) Checkpoint activation in response to
double-strand breaks requires the Mre11/Rad50/Xrs2 complex. Nat Cell Biol
3: 844–847.
49. Enserink JM, Kolodner RD (2010) An overview of Cdk1-controlled targets and
processes. Cell Div 5: 11.
50. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, et al. (2000) A
chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407:
395–401.
51. Liang C, Stillman B (1997) Persistent initiation of DNA replication and
chromatin-bound MCM proteins during the cell cycle in cdc6 mutants. Genes
Dev 11: 3375–3386.
52. Nash P, Tang X, Orlicky S, Chen Q, Gertler FB, et al. (2001) Multisite
phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA
replication. Nature 414: 514–521.
53. Piatti S, Bohm T, Cocker JH, Diffley JF, Nasmyth K (1996) Activation of S-
phase-promoting CDKs in late G1 defines a ‘‘point of no return’’ after which
Cdc6 synthesis cannot promote DNA replication in yeast. Genes Dev 10: 1516–
1531.
54. Schwob E, Bohm T, Mendenhall MD, Nasmyth K (1994) The B-type cyclin
kinase inhibitor p40SIC1 controls the G1 to S transition in S. cerevisiae. Cell 79:
233–244.
55. Koivomagi M, Valk E, Venta R, Iofik A, Lepiku M, et al. (2011) Dynamics of
Cdk1 substrate specificity during the cell cycle. Mol Cell 42: 610–623.
56. Kaochar S, Shanks L, Weinert T (2010) Checkpoint genes and Exo1 regulate
nearby inverted repeat fusions that form dicentric chromosomes in Saccharo-
myces cerevisiae. Proc Natl Acad Sci U S A 107: 21605–21610.
57. Sanchez Y, Bachant J, Wang H, Hu F, Liu D, et al. (1999) Control of the DNA
damage checkpoint by chk1 and rad53 protein kinases through distinct
mechanisms. Science 286: 1166–1171.
58. Granata M, Lazzaro F, Novarina D, Panigada D, Puddu F, et al. (2010)
Dynamics of Rad9 Chromatin Binding and Checkpoint Function Are Mediated
by Its Dimerization and Are Cell Cycle-Regulated by CDK1 Activity. PLoS
Genet 6: e1001047. doi:10.1371/journal.pgen.1001047
59. Navadgi-Patil VM, Burgers PM (2009) A tale of two tails: activation of DNA
damage checkpoint kinase Mec1/ATR by the 9-1-1 clamp and by Dpb11/
TopBP1. DNA Repair (Amst) 8: 996–1003.
60. Puddu F, Granata M, Di Nola L, Balestrini A, Piergiovanni G, et al. (2008)
Phosphorylation of the budding yeast 9-1-1 complex is required for Dpb11
function in the full activation of the UV-induced DNA damage checkpoint. Mol
Cell Biol 28: 4782–4793.
61. Gardner R, Putnam CW, Weinert T (1999) RAD53, DUN1 and PDS1 define
two parallel G2/M checkpoint pathways in budding yeast. Embo J 18: 3173–
3185.
62. Ira G, Pellicioli A, Balijja A, Wang X, Fiorani S, et al. (2004) DNA end
resection, homologous recombination and DNA damage checkpoint activation
require CDK1. Nature 431: 1011–1017.
63. van Vugt MA, Gardino AK, Linding R, Ostheimer GJ, Reinhardt HC, et al.
(2010) A mitotic phosphorylation feedback network connects Cdk1, Plk1,
53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. PLoS Biol
8: e1000287. doi:10.1371/journal.pbio.1000287
64. Huertas P, Cortes-Ledesma F, Sartori AA, Aguilera A, Jackson SP (2008) CDK
targets Sae2 to control DNA-end resection and homologous recombination.
Nature 455: 689–692.
65. Limbo O, Chahwan C, Yamada Y, de Bruin RA, Wittenberg C, et al. (2007)
Ctp1 is a cell-cycle-regulated protein that functions with Mre11 complex to
control double-strand break repair by homologous recombination. Mol Cell 28:
134–146.
66. Lazzaro F, Sapountzi V, Granata M, Pellicioli A, Vaze M, et al. (2008) Histone
methyltransferase Dot1 and Rad9 inhibit single-stranded DNA accumulation at
DSBs and uncapped telomeres. Embo J 27: 1502–1512.
67. Grenon M, Costelloe T, Jimeno S, O’Shaughnessy A, Fitzgerald J, et al. (2007)
Docking onto chromatin via the Saccharomyces cerevisiae Rad9 Tudor domain.
Yeast 24: 105–119.
68. Smits VA (2006) Spreading the signal: dissociation of Chk1 from chromatin. Cell
Cycle 5: 1039–1043.
69. Hammet A, Magill C, Heierhorst J, Jackson SP (2007) Rad9 BRCT domain
interaction with phosphorylated H2AX regulates the G1 checkpoint in budding
yeast. EMBO Rep 8: 851–857.
70. Pfander B, Diffley JF (2011) Dpb11 coordinates Mec1 kinase activation with cell
cycle-regulated Rad9 recruitment. EMBO J 30: 4897–4907.
71. Qu M, Yang B, Tao L, Yates JR, 3rd, Russell P, et al. (2012) Phosphorylation-
dependent interactions between Crb2 and Chk1 are essential for DNA damage
checkpoint. PLoS Genet 8: e1002817. doi:10.1371/journal.pgen.1002817
CDK Regulates Rad9/Chk1 Interaction
PLOS Genetics | www.plosgenetics.org 17 April 2013 | Volume 9 | Issue 4 | e1003310
72. Meng Z, Capalbo L, Glover DM, Dunphy WG (2011) Role for casein kinase 1
in the phosphorylation of Claspin on critical residues necessary for the activation
of Chk1. Mol Biol Cell 22: 2834–2847.
73. Kiely PA, Baillie GS, Barrett R, Buckley DA, Adams DR, et al. (2009)
Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like
growth factor I-mediated regulation of focal adhesion kinase. J Biol Chem 284:
20263–20274.
74. Cocker JH, Piatti S, Santocanale C, Nasmyth K, Diffley JF (1996) An essential
role for the Cdc6 protein in forming the pre-replicative complexes of budding
yeast. Nature 379: 180–182.
CDK Regulates Rad9/Chk1 Interaction
PLOS Genetics | www.plosgenetics.org 18 April 2013 | Volume 9 | Issue 4 | e1003310
